Sangamo Therapeutics (SGMO) News Today → Shocking: One AI startup's revenue could surge 4,735% (From Manward Press) (Ad) Free SGMO Stock Alerts $0.65 +0.04 (+6.72%) (As of 05/17/2024 08:54 PM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 19 at 3:33 AM | americanbankingnews.comSangamo Therapeutics' (SGMO) Buy Rating Reiterated at HC WainwrightMay 18 at 4:30 AM | americanbankingnews.comSangamo Therapeutics, Inc. (NASDAQ:SGMO) Given Average Recommendation of "Moderate Buy" by BrokeragesMay 18 at 1:45 AM | americanbankingnews.comQ2 2024 Earnings Estimate for Sangamo Therapeutics, Inc. Issued By HC Wainwright (NASDAQ:SGMO)May 17 at 7:09 AM | marketbeat.comQ2 2024 EPS Estimates for Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Decreased by HC WainwrightSangamo Therapeutics, Inc. (NASDAQ:SGMO - Free Report) - Investment analysts at HC Wainwright decreased their Q2 2024 earnings per share (EPS) estimates for Sangamo Therapeutics in a report issued on Wednesday, May 15th. HC Wainwright analyst P. Trucchio now anticipates that the biopharmaceuticalMay 17 at 5:06 AM | americanbankingnews.comSangamo Therapeutics, Inc. to Post Q1 2025 Earnings of ($0.05) Per Share, HC Wainwright Forecasts (NASDAQ:SGMO)May 16, 2024 | marketbeat.comHC Wainwright Weighs in on Sangamo Therapeutics, Inc.'s Q1 2025 Earnings (NASDAQ:SGMO)Sangamo Therapeutics, Inc. (NASDAQ:SGMO - Free Report) - HC Wainwright issued their Q1 2025 earnings estimates for Sangamo Therapeutics in a research report issued to clients and investors on Wednesday, May 15th. HC Wainwright analyst P. Trucchio expects that the biopharmaceutical company will eaMay 15, 2024 | marketbeat.comSangamo Therapeutics' (SGMO) "Buy" Rating Reiterated at HC WainwrightHC Wainwright reissued a "buy" rating and set a $5.00 price objective on shares of Sangamo Therapeutics in a report on Wednesday.May 12, 2024 | finance.yahoo.comUS$3.50 - That's What Analysts Think Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Is Worth After These ResultsMay 11, 2024 | finance.yahoo.comSangamo Therapeutics First Quarter 2024 Earnings: US$0.27 loss per share (vs US$0.13 profit in 1Q 2023)May 10, 2024 | marketbeat.comSangamo Therapeutics (NASDAQ:SGMO) Issues Earnings ResultsSangamo Therapeutics (NASDAQ:SGMO - Get Free Report) announced its quarterly earnings results on Thursday. The biopharmaceutical company reported ($0.27) EPS for the quarter, missing analysts' consensus estimates of ($0.22) by ($0.05). Sangamo Therapeutics had a negative return on equity of 82.17% and a negative net margin of 146.30%. The business had revenue of $0.48 million during the quarter, compared to analysts' expectations of $8.51 million. During the same period in the previous year, the business earned $0.12 EPS.May 10, 2024 | finance.yahoo.comSangamo Therapeutics Reports Q1 2024 Results: A Deep Dive into Financials and Strategic HighlightsMay 9, 2024 | msn.comSGMO Stock Earnings: Sangamo Therapeutics Misses EPS, Misses Revenue for Q1 2024May 9, 2024 | businesswire.comSangamo Therapeutics Reports Recent Business Highlights and First Quarter 2024 Financial ResultsMay 9, 2024 | finanznachrichten.deSangamo Therapeutics, Inc.: Sangamo Therapeutics Presents Next-Generation Modular Integrase Technology Engineered to Enable Large-Scale Genome EditingMay 9, 2024 | finance.yahoo.comSangamo Therapeutics Presents Next-Generation Modular Integrase Technology Engineered to Enable Large-Scale Genome EditingMay 8, 2024 | markets.businessinsider.comSangamo Therapeutics is about to announce its earnings — here's what Wall Street expectsMay 3, 2024 | marketbeat.comSangamo Therapeutics (SGMO) Scheduled to Post Quarterly Earnings on ThursdaySangamo Therapeutics (NASDAQ:SGMO) will be releasing earnings after the market closes on Thursday, May 9, Zacks reports.May 2, 2024 | businesswire.comSangamo Therapeutics Announces First Quarter 2024 Conference Call and WebcastApril 30, 2024 | wsj.comSangamo Therapeutics Inc.April 23, 2024 | marketbeat.comSangamo Therapeutics, Inc. (NASDAQ:SGMO) Given Consensus Recommendation of "Hold" by BrokeragesShares of Sangamo Therapeutics, Inc. (NASDAQ:SGMO - Get Free Report) have received a consensus recommendation of "Hold" from the seven analysts that are currently covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, three have given a hold rApril 22, 2024 | businesswire.comSangamo Therapeutics to Present Neurology-Focused Pre-Clinical Data From Its Epigenetic Regulation, Capsid Delivery and Genome Engineering Platforms at the 27th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)April 22, 2024 | marketbeat.comStock Traders Purchase Large Volume of Sangamo Therapeutics Call Options (NASDAQ:SGMO)Sangamo Therapeutics, Inc. (NASDAQ:SGMO - Get Free Report) saw some unusual options trading activity on Monday. Investors bought 11,259 call options on the stock. This represents an increase of approximately 2,053% compared to the typical volume of 523 call options.April 2, 2024 | msn.comBiotech Roundtable: Who will bring the next CRISPR drug to market?March 29, 2024 | marketbeat.comSangamo Therapeutics, Inc. (NASDAQ:SGMO) Receives Consensus Recommendation of "Hold" from BrokeragesShares of Sangamo Therapeutics, Inc. (NASDAQ:SGMO - Get Free Report) have received a consensus recommendation of "Hold" from the seven ratings firms that are covering the company, Marketbeat reports. One research analyst has rated the stock with a sell rating, three have assigned a hold rating anMarch 29, 2024 | marketbeat.comSangamo Therapeutics (NASDAQ:SGMO) Share Price Passes Above 200-Day Moving Average of $0.62Sangamo Therapeutics (NASDAQ:SGMO) Stock Price Crosses Above 200-Day Moving Average of $0.62March 25, 2024 | finance.yahoo.comWhat You Need To Know About The Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Analyst Downgrade TodayMarch 21, 2024 | marketbeat.comQ1 2024 Earnings Estimate for Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Issued By HC WainwrightSangamo Therapeutics, Inc. (NASDAQ:SGMO - Free Report) - Investment analysts at HC Wainwright lowered their Q1 2024 earnings estimates for shares of Sangamo Therapeutics in a research note issued on Tuesday, March 19th. HC Wainwright analyst P. Trucchio now forecasts that the biopharmaceutical coMarch 19, 2024 | money.usnews.comSangamo Therapeutics IncMarch 19, 2024 | marketbeat.comSangamo Therapeutics (NASDAQ:SGMO) Given "Buy" Rating at HC WainwrightHC Wainwright reiterated a "buy" rating and issued a $5.00 price target (up from $3.00) on shares of Sangamo Therapeutics in a report on Tuesday.March 18, 2024 | marketbeat.comSangamo Therapeutics' (SGMO) Sector Perform Rating Reaffirmed at Royal Bank of CanadaRoyal Bank of Canada restated a "sector perform" rating and issued a $2.00 target price on shares of Sangamo Therapeutics in a research note on Thursday.March 18, 2024 | marketbeat.comQ1 2024 Earnings Estimate for Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Issued By WedbushSangamo Therapeutics, Inc. (NASDAQ:SGMO - Free Report) - Research analysts at Wedbush issued their Q1 2024 EPS estimates for Sangamo Therapeutics in a research note issued to investors on Thursday, March 14th. Wedbush analyst A. Argyrides anticipates that the biopharmaceutical company will post eMarch 16, 2024 | ca.finance.yahoo.comSGMO Apr 2024 1.500 putMarch 16, 2024 | markets.businessinsider.comAnalysts Conflicted on These Healthcare Names: Veradigm (OtherMDRX), ADC Therapeutics (ADCT) and Sangamo Biosciences (SGMO)March 16, 2024 | finance.yahoo.comSGMO Apr 2024 1.500 callMarch 15, 2024 | finance.yahoo.comSGMO Apr 2024 3.000 callMarch 14, 2024 | finance.yahoo.comSangamo Therapeutics Full Year 2023 Earnings: Misses ExpectationsMarch 13, 2024 | markets.businessinsider.comSangamo Biosciences’ Breakthrough Capsid Technology Spurs Buy RatingMarch 13, 2024 | markets.businessinsider.com4 Analysts Assess Sangamo Therapeutics: What You Need To KnowMarch 13, 2024 | businesswire.comSangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial ResultsMarch 12, 2024 | businesswire.comSangamo Therapeutics Announces Fourth Quarter and Full Year 2023 Conference Call and WebcastMarch 1, 2024 | finance.yahoo.comSangamo Therapeutics, Inc. (SGMO)February 23, 2024 | investing.comSangamo Therapeutics (SGMO) Earnings Dates & ReportsFebruary 17, 2024 | marketbeat.comSangamo Therapeutics, Inc. (NASDAQ:SGMO) Sees Significant Growth in Short InterestSangamo Therapeutics, Inc. (NASDAQ:SGMO - Get Free Report) was the target of a significant growth in short interest during the month of January. As of January 31st, there was short interest totalling 9,980,000 shares, a growth of 9.0% from the January 15th total of 9,160,000 shares. Based on an average trading volume of 1,650,000 shares, the short-interest ratio is currently 6.0 days.February 13, 2024 | markets.businessinsider.comSangamo Biosciences: Hold Rating Amid Regulatory Progress and Financial UncertaintiesFebruary 12, 2024 | markets.businessinsider.comSangamo Therapeutics Reports U.S. And European Regulatory Support For ST-920February 12, 2024 | finance.yahoo.comWith 55% ownership of the shares, Sangamo Therapeutics, Inc. (NASDAQ:SGMO) is heavily dominated by institutional ownersFebruary 12, 2024 | finance.yahoo.comSangamo Therapeutics Announces U.S. FDA Alignment on Abbreviated Pathway to Potential Approval and EMA Prime Eligibility for ST-920 in Fabry DiseaseFebruary 8, 2024 | marketbeat.comSangamo Therapeutics, Inc. (NASDAQ:SGMO) Given Consensus Recommendation of "Hold" by AnalystsSangamo Therapeutics, Inc. (NASDAQ:SGMO - Get Free Report) has earned an average recommendation of "Hold" from the seven research firms that are covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and threeFebruary 7, 2024 | msn.comSangamo’s STAAR Study Shows Promise in Fabry Disease TreatmentFebruary 6, 2024 | marketbeat.comSangamo Therapeutics (NASDAQ:SGMO) Rating Reiterated by HC WainwrightHC Wainwright reiterated a "buy" rating and issued a $3.00 target price on shares of Sangamo Therapeutics in a report on Tuesday. Get Sangamo Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SGMO and its competitors with MarketBeat's FREE daily newsletter. Email Address Elon to Transform U.S. Economy? (Ad)A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth. One company holds a near-total monopoly on it. SGMO Media Mentions By Week SGMO Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SGMO News Sentiment▼0.330.42▲Average Medical News Sentiment SGMO News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SGMO Articles This Week▼142▲SGMO Articles Average Week Get Sangamo Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SGMO and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: CRIS News SABS News AGEN News BLUE News DBVT News BCAB News LIFE News MOLN News OMGA News SCLX News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:SGMO) was last updated on 5/20/2024 by MarketBeat.com Staff From Our PartnersThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 MediaElon’s New Device is About to Shock the WorldInvestorPlaceBiden Nomination CANCELED?The Freeport SocietyShocking: One AI startup's revenue could surge 4,735%Manward Press"The Biggest Drug Ever" Is ComingBehind the MarketsProtect Your Bank Account Before It’s Too LateWeiss RatingsExposed: 10 CENT Crypto to Explode May 20th?True Market Insiders41 banks launch ‘crypto dollar’Stansberry Research Adding Choose a watchlist: Watchlist My Default Watchlist Adding Sangamo Therapeutics, Inc. You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
